Emixustat for Proliferative Diabetic Retinopathy

Our approach to Diabetic Retinopathy: Emixustat hydrochloride


Modulation of the visual cycle is a novel approach to treating Diabetic Retinopathy (DR). The retina has a higher metabolic rate in the dark than in light, using more energy and oxygen. Slowing the visual cycle with emixustat may be able to mimic some aspects of the light-exposed retina and therefore reduce the metabolic burden of the eye. This includes reducing the retina's oxygen demand, which may slow the progression of diabetic retinopathy - a condition in which decreased oxygen supply plays a significant role. Preclinical evidence supports a mechanism of action in which emixustat effectively reduces oxygen consumption under dark conditions.

Unlike current invasive treatments, emixustat is orally administered. Oral treatment would transform the therapeutic landscape, which currently encompasses laser therapy, surgery, and intravitreal injections - all invasive procedures with corresponding risks of complications. Emixustat has the potential to shift the treatment paradigm in DR.

*PDR: Proliferative Diabetic Retinopathy

*NPDR: Non-proliferative Diabetic Retinopathy

*DME: Diabetic Macular Edema